Key facts: Aytu BioPharma Accepts $56M Buyout; Q1 Revenue Up 6.9%
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.